Comparison of impedance cardiography with invasive hemodynamic measurements in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy

Drazner, Mark H.; Thompson, Brenda; Rosenberg, Paul B.; Kaiser, Patricia A.; Boehrer, James D.; Baldwin, Brian J.; Dries, Daniel L.; Yancy, Clyde W.

doi:10.1016/s0002-9149(02)02257-9

Cited by 122 publications

(91 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Secondly, the previous study was not placebocontrolled for PD 123319 infusion, which may have resulted in time effects on blood pressure. Finally, the population in the previous study were younger (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31) years, compared with 18-55 years in the present study).…”

Section: Parametersupporting

confidence: 43%

See 1 more Smart Citation

Effects of Intravenous PD 123319 on Haemodynamic and Arterial Stiffness Indices in Healthy Volunteers

Brillante

Johnstone

Howes

2005

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

Relatively little is known about the functional expression of cardiovascular angiotensin type 2 (AT 2 )-receptors in healthy young adult humans. We performed a randomised, placebo-controlled crossover study of the effects of intravenous administration of the selective AT 2 -receptor antagonist PD 123319 on haemodynamics and arterial stiffness in normal volunteers. Sixteen normal subjects aged 29.9 ± 13.8 years (range 18-30 years) received an intravenous infusion of PD 123319 (10 mcg/minute for 5 minutes) and placebo, separated by one week. Haemodynamics (cardiac index, stroke index and systemic vascular resistance) were measured non-invasively using a BioZ.com thoracic impedance detection system. Blood pressure was measured from an arm cuff using oscillometry. Stiffness index, a measure of arterial stiffness, was measured using a PulseTrace recorder. No significant changes in blood pressure (p=0.92), cardiac index (p=0.52), stroke index (p=0.61), systemic vascular resistance index (p=0.32) or stiffness index (p=0.57) was demonstrated following PD 123319 infusion, compared with placebo.

show abstract

Section: Parametersupporting

confidence: 43%

“…The accuracy and reproducibility of this device has been investigated and validated. [16][17][18][19][20] For both arterial stiffness and haemodynamic parameters, baseline recordings were measured at one-minute intervals for a total of 5 minutes. Values were averaged to give a mean baseline result.…”

Section: Methodsmentioning

confidence: 99%

Effects of Intravenous PD 123319 on Haemodynamic and Arterial Stiffness Indices in Healthy Volunteers

Brillante

Johnstone

Howes

2005

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

show abstract

“…However, only 14 patients (7%) in the safety analysis population had tricuspid valvular disorders that may have been associated with severe tricuspid regurgitation reported in their medical history. Furthermore, the thermodilution technique, which strongly correlates with the Fick oxygen technique, 28 was consistently used to measure cardiac output at baseline and after 16 weeks of study drug therapy. We cannot exclude the possibility that the pulmonary vasodilator effect of riociguat was accompanied by the development of ventilation/perfusion mismatching and that some of the increase in cardiac index observed in patients receiving riociguat occurred to mitigate that effect and to maintain peripheral oxygen delivery.…”

Section: C Cardiac Index (Ci) D Stroke Volume Index (Svi) E Pulmmentioning

confidence: 99%

Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction

et al. 2013

View full text Add to dashboard Cite

P ulmonary hypertension (PH) caused by systolic left ventricular dysfunction (sLVD) is associated with high levels of morbidity and mortality in patients with heart failure (HF). 1Established HF therapies such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, and diuretics may be effective by improving left ventricular (LV) function and reducing LV filling pressure, but currently available agents do not affect the pulmonary circulation. 1 To date, randomized trials of agents targeted at the pulmonary vasculature either have failed to demonstrate benefit in patients with PH-sLVD or have not been adequately powered to detect changes in morbidity or mortality, 2-5 highlighting an urgent unmet medical need. Editorial see p 475 Clinical Perspective on p 511Background-Pulmonary hypertension caused by systolic left ventricular dysfunction is associated with significant morbidity and mortality; however, no treatment is approved for this indication. We hypothesized that riociguat, a novel soluble guanylate cyclase stimulator, would have beneficial hemodynamic effects in patients with pulmonary hypertension caused by systolic left ventricular dysfunction. Methods and Results-Overall, 201 patients with heart failure resulting from pulmonary hypertension caused by systolic left ventricular dysfunction were randomized to double-blind treatment with oral placebo or riociguat (0.5, 1, or 2 mg 3 times daily) for 16 weeks in 4 parallel arms. The primary outcome was the placebo-corrected change from baseline at week 16 in mean pulmonary artery pressure. Although the decrease in mean pulmonary artery pressure in the riociguat 2 mg group (−6.1±1.3 mm Hg; P<0.0001 versus baseline) was not significantly different from placebo (P=0.10), cardiac index (0.4 L·min ; 95% confidence interval, 2.0-8.4; P=0.0018) were significantly increased without changes in heart rate or systemic blood pressure compared with placebo. Both pulmonary (−46.6 dynes·s Bonderman et al Riociguat for PH-sLVD 503Riociguat is a novel soluble guanylate cyclase (sGC) stimulator that is under investigation as a new approach to treat PH. 6 HF-and PH-related diseases are characterized by endothelial dysfunction with a concomitant decrease in availability of nitric oxide. 1,7,8 Riociguat has a dual mode of action: It sensitizes sGC to endogenous nitric oxide and directly stimulates sGC independently of nitric oxide.9 Riociguat induces vasodilation, and results from animal studies have demonstrated additional antifibrotic, antiproliferative, and anti-inflammatory effects.6,9,10 In a hemodynamic study in patients with reduced LV ejection fraction (≤45%) and mean pulmonary artery pressure (mPAP) ≥25 mm Hg, single doses of the sGC stimulator BAY 60-4552 reduced mPAP, pulmonary capillary wedge pressure, systemic vascular resistance (SVR), and pulmonary vascular resistance (PVR) and decreased systemic arterial blood pressure (BP).10,11 Thus, riociguat may be a promising novel treatment for PH-sLVD in patients with HF.To characterize the ...

show abstract

“…Mede alterações instantâneas, batimento a batimento, da impedância eléctrica e, através de algoritmos, infere parâmetros como o volume sistólico, o débito cardíaco e o fl uido torácico total (FTT), entre outros. A última geração de aparelhos de BET tem vindo a ganhar relevo, com estudos comprovando a sua efi cácia em várias patologias e correlação com determinações invasivas [7][8][9] . O FTT, um novo parâmetro avaliado de forma não invasiva por BET, é um indicador do volume total de fl uidos no tórax, tanto intra como extracelulares, em particular a nível do pulmão 10 .…”

Section: Introductionunclassified

Fluido torácico total – Um possível determinante da eficácia ventilatória em doentes com insuficiência cardíaca

Valente

Feliciano

Soares

et al. 2011

Revista Portuguesa de Cardiologia

View full text Add to dashboard Cite

Comparison of impedance cardiography with invasive hemodynamic measurements in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy

Cited by 122 publications

References 5 publications

Effects of Intravenous PD 123319 on Haemodynamic and Arterial Stiffness Indices in Healthy Volunteers

Effects of Intravenous PD 123319 on Haemodynamic and Arterial Stiffness Indices in Healthy Volunteers

Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction

Fluido torácico total – Um possível determinante da eficácia ventilatória em doentes com insuficiência cardíaca

Contact Info

Product

Resources

About